Age, Biography and Wiki
Kelly Chibale was born on 1964 in Zambia, is an Organic chemistry professor (born 1964). Discover Kelly Chibale's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is he in this year and how he spends money? Also learn how he earned most of networth at the age of 57 years old?
| Popular As |
N/A |
| Occupation |
N/A |
| Age |
57 years old |
| Zodiac Sign |
N/A |
| Born |
1967 |
| Birthday |
|
| Birthplace |
Zambia |
| Nationality |
Zambia
|
We recommend you to check the complete list of Famous People born on .
He is a member of famous professor with the age 57 years old group.
Kelly Chibale Height, Weight & Measurements
At 57 years old, Kelly Chibale height not available right now. We will update Kelly Chibale's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.
| Physical Status |
| Height |
Not Available |
| Weight |
Not Available |
| Body Measurements |
Not Available |
| Eye Color |
Not Available |
| Hair Color |
Not Available |
Dating & Relationship status
He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.
| Family |
| Parents |
Not Available |
| Wife |
Not Available |
| Sibling |
Not Available |
| Children |
Not Available |
Kelly Chibale Net Worth
His net worth has been growing significantly in 2023-2024. So, how much is Kelly Chibale worth at the age of 57 years old? Kelly Chibale’s income source is mostly from being a successful professor. He is from Zambia. We have estimated Kelly Chibale's net worth, money, salary, income, and assets.
| Net Worth in 2024 |
$1 Million - $5 Million |
| Salary in 2024 |
Under Review |
| Net Worth in 2023 |
Pending |
| Salary in 2023 |
Under Review |
| House |
Not Available |
| Cars |
Not Available |
| Source of Income |
professor |
Kelly Chibale Social Network
Timeline
Kelly Chibale PhD, FRSSAf, FRSC (born 1964) is professor of organic chemistry at the University of Cape Town, and the founder and director of H3D research center.
He studied chemistry at the University of Zambia, graduating in 1987.
Chibale worked at Kafironda Explosives in Mufulira.
As there were no opportunities for graduate studies in Zambia, he moved to the University of Cambridge for his PhD, working in Stuart Warren's group on synthetic organic chemistry of optically active molecules.
He was funded by a Cambridge Livingstone Trust scholarship.
Following his PhD, Chibale joined the University of Liverpool as a Sir William Ramsay British Research Fellow.
He developed optically active alcohols using lanthanides.
In 1994 he joined the Scripps Research Institute, creating complicated natural molecules from organic building blocks.
He began to explore angiogenesis inhibitors, which can be used to stop cancer cells developing new blood vessels.
Inspired by medicinal chemistry, Chibale returned to Africa in 1996, joining the research group of James Bull.
In 2002 he joined the University of California, San Francisco as a Sandler Foundation Fellow.
He was elected a Professor in 2007 and a Life Fellow of the University of Cape Town in 2009.
His group studies treatments for HIV, cancer, malaria and hypertension.
He set up collaborations and exchange programs for South African students to learn how to translate basic science into potential products.
In 2008 he took a sabbatical, working as a Fulbright scholar at the University of Pennsylvania and Pfizer.
He was elected a Fellow of the Royal Society of South Africa in 2009.
In 2010 he founded H3D, the first drug discovery centre at the University of Cape Town.
The research program received significant media attention and has been supported by Bill Gates.
In 2012 Chibale's group discovered MMV390048, an aminopyridine compound that can be used as a single-dose treatment for malaria.
It was the first antimalarial medicine to enter phase 1 human studies in Africa.
He was elected a Fellow of the Royal Society of Chemistry in 2014.
In 2016 they discovered another antimalarial compound, UCT943.
He has written for The Conversation about how Africa's medicinal drug research can paved the landscape for health innovation in the continent.
Today he holds a Chair of Drug Discovery at the University of Cape Town.
In 2016 the Royal Society of Chemistry recognised him as one of their 175 Faces of chemistry.
In 2018 he was recognized as one of Fortune magazine's top 50 World's Greatest Leaders.
His research focuses on target-directed inhibitors.
Chibale grew up without electricity or running water in Mpika district, Zambia.
His parents are Elizabeth Malekano Chanda and Harrison Chibale.
In 2018 H3D partnered with Merck & Co. to build Africa's capacity for research.
